ライフサイエンスコーパス: pulmonary aspergillosis

1 d A. fumigatus avirulent in a mouse model of pulmonary aspergillosis.

2 idia either in vitro or in a murine model of pulmonary aspergillosis.

3 als for comprehension of the pathogenesis of pulmonary aspergillosis.

4 s is the causative agent of allergic broncho-pulmonary aspergillosis.

5 , and the remaining 165 patients no invasive pulmonary aspergillosis.

6 d is avirulent in a murine model of invasive pulmonary aspergillosis.

7 tic cell transplant recipients with invasive pulmonary aspergillosis.

8 osuppressed mice from experimentally induced pulmonary aspergillosis.

9 nt in two distinct murine models of invasive pulmonary aspergillosis.

10 of haematogenously disseminated and invasive pulmonary aspergillosis.

11 ion in vitro and in mouse models of invasive pulmonary aspergillosis.

12 be antagonistic in the treatment of invasive pulmonary aspergillosis.

13 ung tissue recovered from mice with invasive pulmonary aspergillosis.

14 -mediated pH response in the pathogenesis of pulmonary aspergillosis.

15 f A. terreus to AmB in experimental invasive pulmonary aspergillosis.

16 ent a new strategy for treatment of invasive pulmonary aspergillosis.

17 d animals against subsequent lethal invasive pulmonary aspergillosis.

18 ay key roles in host defense against primary pulmonary aspergillosis.

19 important proximal signal in murine invasive pulmonary aspergillosis.

20 There was one transplant-related death from pulmonary aspergillosis.

21 t (n = 524), 79 patients had proven invasive pulmonary aspergillosis (15.1%).

22 2(-/-) mice displayed high susceptibility to pulmonary aspergillosis, a phenotype associated with a p

23 etermining BAL GM levels in the diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts

24 .9%, likely reflecting the low prevalence of pulmonary aspergillosis among nonimmunosuppressed patien

25 Incidences of invasive pulmonary aspergillosis, an infection caused predominant

26 ions include invasive aspergillosis, chronic pulmonary aspergillosis and bronchitis.

27 covered as the etiological agent of invasive pulmonary aspergillosis and had reduced in vitro suscept

28 plored targets for the treatment of invasive pulmonary aspergillosis and may potentiate both innate i

29 is known about the pathogenesis of invasive pulmonary aspergillosis and the relationship between the

30 ally successful if initiated early, although pulmonary aspergillosis and zygomycosis are portentous a

31 pulmonary aspergillosis, chronic necrotizing pulmonary aspergillosis, and aspergilloma.

32 at the inflammatory response during invasive pulmonary aspergillosis, and in particular the IL-1 axis

33 This is particularly true for invasive pulmonary aspergillosis, as so far, sources of (macro)el

34 n of neutrophils, animals developed invasive pulmonary aspergillosis, associated with delayed influx

35 c fibrosis patients without allergic broncho-pulmonary aspergillosis but sensitized to A. fumigatus a

36 spergillus fumigatus causes chronic cavitary pulmonary aspergillosis (CCPA) and allergic bronchopulmo

37 aspergillosis, two each with acute invasive pulmonary aspergillosis, chronic necrotizing pulmonary a

38 vitro, could account for chronic necrotizing pulmonary aspergillosis (CNPA), which is seen most commo

39 Chronic pulmonary aspergillosis (CPA) is an infectious disease t

40 body improves survival of mice with invasive pulmonary aspergillosis, demonstrating the potential of

41 In invasive pulmonary aspergillosis, direct invasion and occlusion o

42 Asp f 6 helped distinguish allergic broncho-pulmonary aspergillosis from A. fumigatus sensitization

43 Blood from three patients with pulmonary aspergillosis had positive PCR results: one pa

44 ecruitment in neutropenic mice with invasive pulmonary aspergillosis (IA).

45 detecting galactomannan (GM) for diagnosing pulmonary aspergillosis in 73 nonimmunocompromised patie

46 By use of a model of invasive pulmonary aspergillosis in corticosteroid-treated CF-1 m

47 respiratory tract colonization from invasive pulmonary aspergillosis in critically ill patients.

48 Therefore, we evaluated susceptibility to pulmonary aspergillosis in globally NADPH oxidase-defici

49 was assessed using a murine model of primary pulmonary aspergillosis in immunocompetent Crl:CF-1 mice

50 us is an important pathogen causing invasive pulmonary aspergillosis in immunocompromised patients.

51 ungal clearance during experimental invasive pulmonary aspergillosis in neutropenic mice.

52 Pulmonary aspergillosis in nonimmunocompromised hosts, a

53 ultaneous treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabb

54 tion triazole, against experimental invasive pulmonary aspergillosis in persistently neutropenic rabb

55 undamental insights into the pathogenesis of pulmonary aspergillosis in the immunocompromised host.

56 ergillus colonization from putative invasive pulmonary aspergillosis in this patient group.

57 Risk factors for invasive pulmonary aspergillosis (IPA) after kidney transplantati

58 tic factors and optimal therapy for invasive pulmonary aspergillosis (IPA) after kidney transplantati

59 age (BAL) fluid in the diagnosis of invasive pulmonary aspergillosis (IPA) among solid-organ transpla

60 gal therapy on an LFD developed for invasive pulmonary aspergillosis (IPA) detection.

61 Invasive pulmonary aspergillosis (IPA) is a frequently fatal infe

62 Invasive pulmonary aspergillosis (IPA) is a life-threatening lung

63 Invasive pulmonary aspergillosis (IPA) is a significant complicat

64 e to unresolved inflammation during invasive pulmonary aspergillosis (IPA) is associated with a poor

65 Invasive pulmonary aspergillosis (IPA) is frequent and often fata

66 Invasive pulmonary aspergillosis (IPA) is often a lethal entity i

67 Invasive pulmonary aspergillosis (IPA) is one of the major compli

68 cation of the causative organism in invasive pulmonary aspergillosis (IPA) is recommended.

69 Invasive pulmonary aspergillosis (IPA) is the most common manifes

70 Diagnosis of invasive pulmonary aspergillosis (IPA) remains a major challenge

71 Invasive pulmonary aspergillosis (IPA) remains an important cause

72 ontribute to therapeutic failure in invasive pulmonary aspergillosis (IPA).

73 e gold standard test for diagnosing invasive pulmonary aspergillosis (IPA).

74 n antifungal immunity in a model of invasive pulmonary aspergillosis (IPA).

75 rst-line agent for the treatment of invasive pulmonary aspergillosis (IPA).

76 y facilitate the early diagnosis of invasive pulmonary aspergillosis (IPA).

77 aluation of patients with suspected invasive pulmonary aspergillosis (IPA).

78 ynamics of caspofungin (CAS) during invasive pulmonary aspergillosis (IPA).

79 Invasive pulmonary aspergillosis is a common and devastating comp

80 Invasive pulmonary aspergillosis is a devastating complication of

81 Invasive pulmonary aspergillosis is a devastating complication of

82 Invasive pulmonary aspergillosis is a leading cause of infection-

83 Pulmonary aspergillosis is a lethal mold infection in th

84 Invasive pulmonary aspergillosis is acquired through inhalation o

85 Invasive pulmonary aspergillosis is an emerging devastating infec

86 Invasive pulmonary aspergillosis is an important cause of morbidi

87 The diagnosis of pulmonary aspergillosis is difficult, since the recovery

88 mononuclear cells into the lung in invasive pulmonary aspergillosis is in part mediated by MIP-1 alp

89 rs, and antifungal drug therapy for invasive pulmonary aspergillosis may be further understood.

90 nd in situ angiogenesis in a murine invasive pulmonary aspergillosis model.

91 ced mutant was hypervirulent in the invasive pulmonary aspergillosis murine model system and showed i

92 pulmonary aspergillosis, chronic necrotizing pulmonary aspergillosis, or invasive aspergillosis (IA),

93 ngal lung burdens in a rat model of invasive pulmonary aspergillosis (p<0.05) compared to treatment w

94 kely to serve as an S source during invasive pulmonary aspergillosis since a sulfate transporter muta

95 s and in nine patients with allergic broncho-pulmonary aspergillosis (two with cystic fibrosis and se

96 Six patients had pulmonary aspergillosis, two each with acute invasive pu

97 Invasive pulmonary aspergillosis was an independent risk factor f

98 Invasive pulmonary aspergillosis was defined according to Europea

99 Probable or proven invasive pulmonary aspergillosis was diagnosed in 14% of our stud

100 l alkalinization in the host defense against pulmonary aspergillosis, we observed high morbidity of p